Melanocortins protect against multiple organ dysfunction syndrome in mice
Melanocortins protect against multiple organ dysfunction syndrome in mice
复制标题
DOI:
10.1111/j.1476-5381.2010.01098.x
复制
发表时间:
2011-02-01
影响因子:
7.3
通讯作者:
Squadrito, Francesco
中科院分区:
文献类型:
--
作者:
Bitto, Alessandra;Polito, Francesca;Squadrito, Francesco
BACKGROUND AND PURPOSEMelanocortins reverse circulatory shock and improve survival by counteracting the systemic inflammatory response, and through the activation of the vagus nerve-mediated cholinergic anti-inflammatory pathway. To gain insight into the potential therapeutic value of melanocortins against multiple organ damage following systemic inflammatory response, here we investigated the effects of the melanocortin analogue [Nle4, D-Phe7]alpha-MSH (NDP-alpha-MSH) in a widely used murine model of multiple organ dysfunction syndrome (MODS).EXPERIMENTAL APPROACHMODS was induced in mice by a single intraperitoneal injection of lipopolysaccharide followed, 6 days later (= day 0), by zymosan. After MODS or sham MODS induction, animals were randomized to receive intraperitoneally NDP-alpha-MSH (340 mu g center dot kg-1 day) or saline for up to 16 days. Additional groups of MODS mice were concomitantly treated with the melanocortin MC4 receptor antagonist HS024, or the nicotinic acetylcholine receptor antagonist chlorisondamine, and NDP-alpha-MSH.KEY RESULTSAt day 7, in the liver and lung NDP-alpha-MSH, significantly reduced mRNA expression of tumour necrosis factor-alpha (TNF-alpha), increased mRNA expression of interleukin-10 and improved the histological picture, as well as reduced TNF-alpha plasma levels; furthermore, NDP-alpha-MSH dose-dependently increased survival rate, as assessed throughout the 16 day observation period. HS024 and chlorisondamine prevented all the beneficial effects of NDP-alpha-MSH in MODS mice.CONCLUSIONS AND IMPLICATIONSThese data indicate that NDP-alpha-MSH protects against experimental MODS by counteracting the systemic inflammatory response, probably through brain MC4 receptor-triggered activation of the cholinergic anti-inflammatory pathway. These findings reveal previously undescribed effects of melanocortins and could have clinical relevance in the MODS setting.